SERINA THERAPEUTICS INC. (SER) Stock News

USA - NYSEARCA:SER - US81751A1088 - Common Stock

3.76 USD

-0.06 (-1.49%)

Last: 11/18/2025, 8:04:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

SER Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

16 days ago - By: Stocktwits - Mentions: VTI VXF

News Image

Serina Therapeutics Stock Slumps Pre-Market After FDA Places Hold On Application To Initiate Clinical Trials For Experimental Therapy

16 days ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Provides Regulatory Update on SER-252 Program

a month ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors

a month ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s Disease

2 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease

3 months ago - By: Stocktwits

News Image

Why Did Serina Therapeutics Stock Rocket 37% After The Bell Today?

2 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: Benzinga - Mentions: CGC CASI FBIO AQB ...

12 Health Care Stocks Moving In Friday's After-Market Session

3 months ago - By: Benzinga - Mentions: EPIX LPTX MOLN NBTX ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

3 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson’s Disease under 505(b)(2) NDA Pathway

3 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

4 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

4 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference

4 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

5 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

5 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

5 months ago - By: Serina Therapeutics, Inc.

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

5 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

5 months ago - By: Serina Therapeutics, Inc.

Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"

6 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

6 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

6 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

7 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

7 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

7 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

8 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

8 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

8 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

9 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

10 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

10 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Announces Sale of UniverXome Subsidiary

10 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors